Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2009

01.08.2009 | Endocrine Tumors

When Is Prophylactic Thyroidectomy Indicated for Patients with the RET Codon 609 Mutation?

verfasst von: Daniel Calva, MD, Thomas M. O’Dorisio, MD, M. Sue O’Dorisio, MD, Geeta Lal, MD, Sonia Sugg, MD, Ronald J. Weigel, MD, James R. Howe, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Mutations in the RET proto-oncogene cause multiple endocrine neoplasia type 2A (MEN2A), and prophylactic thyroidectomy has generally been recommended before the age of 5 years. Patients with codon 609 mutations develop MTC at a later age and therefore the timing of prophylactic thyroidectomy is less clear. We report a three-generation family with C609Y RET mutation where members having prophylactic or therapeutic thyroidectomy call the current recommendations for age at thyroidectomy into question.

Methods

Sixteen family members underwent thyroidectomy, for which clinical, laboratory, and pathological data were analyzed. A literature review of RET codon 609 mutations was carried out.

Results

Data were collected from 16 patients from this 38-member kindred. None of these affected members had pheochromocytoma, and one had a parathyroid adenoma. Nine of 16 patients had MTC (mean age 44.7 years, range 29–59 years) and elevated basal calcitonin levels; 6 of these 9 had lymph node metastases. Two patients had C-cell hyperplasia (CCH) at ages 18 and 37 years, and five patients had normal thyroid pathology (mean age 16 years, range 5–37 years). In the literature, a family with C609Y mutation was reported, with 15 members having MTC (mean age 42 years, range 21–59 years), and 6 with CCH (mean age 24 years, range 15–37 years).

Conclusion

The youngest patient with C609Y RET mutation and MTC was 21 years old, and the youngest patient with CCH was 15 years old at diagnosis. These data suggest that patients with RET C609Y mutations can delay thyroidectomy until 10–15 years of age, with annual calcitonin screening prior to thyroidectomy.
Literatur
1.
Zurück zum Zitat Howe JR, Norton JA, Wells SA, Jr. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery. 1993;114:1070–7.PubMed Howe JR, Norton JA, Wells SA, Jr. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery. 1993;114:1070–7.PubMed
2.
Zurück zum Zitat Moore SW, Zaagl MG. Multiple endocrine neoplasia syndromes, children, Hirschsprung’s disease and RET. Pediatr Surg Int. 2008;24:521–30.PubMedCrossRef Moore SW, Zaagl MG. Multiple endocrine neoplasia syndromes, children, Hirschsprung’s disease and RET. Pediatr Surg Int. 2008;24:521–30.PubMedCrossRef
3.
Zurück zum Zitat Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851–6.PubMedCrossRef Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2:851–6.PubMedCrossRef
4.
Zurück zum Zitat Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–60.PubMedCrossRef Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–60.PubMedCrossRef
5.
Zurück zum Zitat Iwashita T, Kato M, Murakami H, et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene. 1999;18:3919–22.PubMedCrossRef Iwashita T, Kato M, Murakami H, et al. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene. 1999;18:3919–22.PubMedCrossRef
6.
Zurück zum Zitat Ito S, Iwashita T, Asai N, et al. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung’s disease phenotype. Cancer Res. 1997;57:2870–2.PubMed Ito S, Iwashita T, Asai N, et al. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung’s disease phenotype. Cancer Res. 1997;57:2870–2.PubMed
7.
Zurück zum Zitat Ponder BA, Smith D. The MEN II syndromes and the role of the ret proto-oncogene. Adv Cancer Res. 1996;70:179–222.PubMedCrossRef Ponder BA, Smith D. The MEN II syndromes and the role of the ret proto-oncogene. Adv Cancer Res. 1996;70:179–222.PubMedCrossRef
8.
Zurück zum Zitat Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.PubMedCrossRef Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–71.PubMedCrossRef
9.
Zurück zum Zitat Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276:1575–9.PubMedCrossRef Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276:1575–9.PubMedCrossRef
10.
Zurück zum Zitat Mulligan LM, Eng C, Attie T, et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet. 1994;3:2163–7.PubMedCrossRef Mulligan LM, Eng C, Attie T, et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet. 1994;3:2163–7.PubMedCrossRef
11.
Zurück zum Zitat Quayle FJ, Fialkowski EA, Benveniste R, Moley JF. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery. 2007;142:800–5;discussion 805 e1. Quayle FJ, Fialkowski EA, Benveniste R, Moley JF. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery. 2007;142:800–5;discussion 805 e1.
12.
Zurück zum Zitat Zaydfudim V, Stover DG, Caro SW, Phay JE. Presentation of a medullary endocrine neoplasia 2A kindred with Cushing’s syndrome. Am Surg. 2008;74:659–61.PubMed Zaydfudim V, Stover DG, Caro SW, Phay JE. Presentation of a medullary endocrine neoplasia 2A kindred with Cushing’s syndrome. Am Surg. 2008;74:659–61.PubMed
13.
Zurück zum Zitat Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg. 2003;138:409–16;discussion 416. Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg. 2003;138:409–16;discussion 416.
14.
Zurück zum Zitat Machens A, Brauckhoff M, Holzhausen HJ, et al. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2005;90:3999–4003.PubMedCrossRef Machens A, Brauckhoff M, Holzhausen HJ, et al. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2005;90:3999–4003.PubMedCrossRef
15.
Zurück zum Zitat Decker RA, Peacock ML. Occurrence of MEN 2a in familial Hirschsprung’s disease: a new indication for genetic testing of the RET proto-oncogene. J Pediatr Surg. 1998;33:207–14.PubMedCrossRef Decker RA, Peacock ML. Occurrence of MEN 2a in familial Hirschsprung’s disease: a new indication for genetic testing of the RET proto-oncogene. J Pediatr Surg. 1998;33:207–14.PubMedCrossRef
16.
Zurück zum Zitat Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet. 1998;7:129–34.PubMedCrossRef Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet. 1998;7:129–34.PubMedCrossRef
17.
Zurück zum Zitat Halling KC, Bufill JA, Cotter M, et al. Age-related disease penetrance in a large medullary thyroid cancer family with a codon 609 RET gene mutation. Mol Diagn. 1997;2:277–86.PubMedCrossRef Halling KC, Bufill JA, Cotter M, et al. Age-related disease penetrance in a large medullary thyroid cancer family with a codon 609 RET gene mutation. Mol Diagn. 1997;2:277–86.PubMedCrossRef
18.
Zurück zum Zitat Munnes M, Fanaei S, Schmitz B, et al. Familial form of Hirschsprung disease: nucleotide sequence studies reveal point mutations in the RET proto-oncogene in two of six families but not in other candidate genes. Am J Med Genet. 2000;94:19–27.PubMedCrossRef Munnes M, Fanaei S, Schmitz B, et al. Familial form of Hirschsprung disease: nucleotide sequence studies reveal point mutations in the RET proto-oncogene in two of six families but not in other candidate genes. Am J Med Genet. 2000;94:19–27.PubMedCrossRef
19.
Zurück zum Zitat Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007;92:4725–9.PubMedCrossRef Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007;92:4725–9.PubMedCrossRef
20.
Zurück zum Zitat Koch CA, Brouwers FM, Vortmeyer AO, et al. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer. 2006;6:131. Koch CA, Brouwers FM, Vortmeyer AO, et al. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer. 2006;6:131.
21.
Zurück zum Zitat Zakrzewska A, Makowska AM, Bar-Andziak E. [Late onset of medullary thyroid carcinoma with bilateral adrenal pheochromocytomas in the case of patient with MEN 2]. Pol Merkur Lekarski. 2004;17:633–7.PubMed Zakrzewska A, Makowska AM, Bar-Andziak E. [Late onset of medullary thyroid carcinoma with bilateral adrenal pheochromocytomas in the case of patient with MEN 2]. Pol Merkur Lekarski. 2004;17:633–7.PubMed
22.
Zurück zum Zitat Simon S, Pavel M, Hensen J, et al. Multiple endocrine neoplasia 2A syndrome: surgical management. J Pediatr Surg. 2002;37:897–900.PubMedCrossRef Simon S, Pavel M, Hensen J, et al. Multiple endocrine neoplasia 2A syndrome: surgical management. J Pediatr Surg. 2002;37:897–900.PubMedCrossRef
23.
Zurück zum Zitat Fitze G, Schreiber M, Hohenberger W, et al. Interaction of RET proto-oncogene codon 609 germline mutations with RET haplotypes characterized by c.135G > A alleles modifying MEN 2A or HSCR phenotypes. Am J Med Genet A. 2004;129A:323–5.PubMedCrossRef Fitze G, Schreiber M, Hohenberger W, et al. Interaction of RET proto-oncogene codon 609 germline mutations with RET haplotypes characterized by c.135G > A alleles modifying MEN 2A or HSCR phenotypes. Am J Med Genet A. 2004;129A:323–5.PubMedCrossRef
24.
Zurück zum Zitat Kinlaw WB, Scott SM, Maue RA, et al. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2005;63:676–82.CrossRef Kinlaw WB, Scott SM, Maue RA, et al. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2005;63:676–82.CrossRef
25.
Zurück zum Zitat Patocs A, Karadi E, Toth M, et al. Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre. Eur J Cancer Prev. 2004;13:403–9.PubMedCrossRef Patocs A, Karadi E, Toth M, et al. Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre. Eur J Cancer Prev. 2004;13:403–9.PubMedCrossRef
26.
Zurück zum Zitat Klein I, Esik O, Homolya V, et al. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. J Endocrinol. 2001;170:661–6.PubMedCrossRef Klein I, Esik O, Homolya V, et al. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. J Endocrinol. 2001;170:661–6.PubMedCrossRef
27.
Zurück zum Zitat Igaz P, Patocs A, Racz K, et al. Occurrence of pheochromocytoma in a MEN2A family with codon 609 mutation of the RET proto-oncogene. J Clin Endocrinol Metab. 2002;87:2994. Igaz P, Patocs A, Racz K, et al. Occurrence of pheochromocytoma in a MEN2A family with codon 609 mutation of the RET proto-oncogene. J Clin Endocrinol Metab. 2002;87:2994.
28.
Zurück zum Zitat Kusafuka T, Wang Y, Puri P. Novel mutations of the endothelin-B receptor gene in isolated patients with Hirschsprung’s disease. Hum Mol Genet. 1996;5:347–9.PubMedCrossRef Kusafuka T, Wang Y, Puri P. Novel mutations of the endothelin-B receptor gene in isolated patients with Hirschsprung’s disease. Hum Mol Genet. 1996;5:347–9.PubMedCrossRef
29.
Zurück zum Zitat Pingault V, Bondurand N, Kuhlbrodt K, et al. SOX10 mutations in patients with Waardenburg–Hirschsprung disease. Nat Genet. 1998;18:171–3.PubMedCrossRef Pingault V, Bondurand N, Kuhlbrodt K, et al. SOX10 mutations in patients with Waardenburg–Hirschsprung disease. Nat Genet. 1998;18:171–3.PubMedCrossRef
30.
Zurück zum Zitat Toledo SP, dos Santos MA, Toledo Rde A, Lourenco Junior DM. Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics. 2006;61:59–70.PubMedCrossRef Toledo SP, dos Santos MA, Toledo Rde A, Lourenco Junior DM. Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics. 2006;61:59–70.PubMedCrossRef
31.
Zurück zum Zitat Sosa JA, Tuggle CT, Wang TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93:3058–65.PubMedCrossRef Sosa JA, Tuggle CT, Wang TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93:3058–65.PubMedCrossRef
32.
Zurück zum Zitat Papi G, Corrado S, Pomponi MG, et al. Concurrent lymph node metastases of medullary and papillary thyroid carcinoma in a case with RET oncogene germline mutation. Endocr Pathol. 2003;14:269–76.PubMedCrossRef Papi G, Corrado S, Pomponi MG, et al. Concurrent lymph node metastases of medullary and papillary thyroid carcinoma in a case with RET oncogene germline mutation. Endocr Pathol. 2003;14:269–76.PubMedCrossRef
33.
Zurück zum Zitat Melillo RM, Cirafici AM, De Falco V, et al. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol. 2004;165:511–21.PubMed Melillo RM, Cirafici AM, De Falco V, et al. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol. 2004;165:511–21.PubMed
34.
Zurück zum Zitat Rossi S, Fugazzola L, De Pasquale L, et al. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature. Endocr Relat Cancer. 2005;12:281–9.PubMedCrossRef Rossi S, Fugazzola L, De Pasquale L, et al. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature. Endocr Relat Cancer. 2005;12:281–9.PubMedCrossRef
35.
Zurück zum Zitat Fazioli F, Piccinini G, Appolloni G, et al. A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma. Thyroid. 2008;18:775–82.PubMedCrossRef Fazioli F, Piccinini G, Appolloni G, et al. A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma. Thyroid. 2008;18:775–82.PubMedCrossRef
36.
Zurück zum Zitat Brauckhoff M, Gimm O, Hinze R, et al. Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation. Thyroid. 2002;12:557–61.PubMedCrossRef Brauckhoff M, Gimm O, Hinze R, et al. Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation. Thyroid. 2002;12:557–61.PubMedCrossRef
37.
Zurück zum Zitat Feldman GL, Edmonds MW, Ainsworth PJ, et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804 M (GTG → ATG) mutation. Surgery. 2000;128:93–8.PubMedCrossRef Feldman GL, Edmonds MW, Ainsworth PJ, et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804 M (GTG → ATG) mutation. Surgery. 2000;128:93–8.PubMedCrossRef
Metadaten
Titel
When Is Prophylactic Thyroidectomy Indicated for Patients with the RET Codon 609 Mutation?
verfasst von
Daniel Calva, MD
Thomas M. O’Dorisio, MD
M. Sue O’Dorisio, MD
Geeta Lal, MD
Sonia Sugg, MD
Ronald J. Weigel, MD
James R. Howe, MD
Publikationsdatum
01.08.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0524-3

Weitere Artikel der Ausgabe 8/2009

Annals of Surgical Oncology 8/2009 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.